Sun Pharma Recalls Over 34k Bottles Of Generic Drug In US Due To Mfg Issues

Sun Pharmaceutical Industries is recalling lots of Diltiazem Hydrochloride extended-release capsules which are used to treat angina, high blood pressure and some types of irregular heartbeats

Topics

Sun Pharma | United States | drugs

Press Trust of India  |  New Delhi 



Sun Pharma

Princeton (New Jersey) based Sun Pharmaceutical Inc is recalling the affected lot due to "Failed Impurity (Deacetyl Diltiazem Hydrochloride) specification during stability testing and failed dissolution testing at FDA laboratory."

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();

Drug major is recalling over 34,000 bottles of a generic medication, used to treat high blood pressure, in the US market due to failed dissolution testing.

As per the US Food and Drug Administration's Enforcement Report, the US-based arm of Sun Pharmaceutical Industries is recalling lots of Diltiazem Hydrochloride extended-release capsules which are used to treat angina, high blood pressure and some types of irregular heartbeats.

Princeton (New Jersey) based Sun Pharmaceutical Inc is recalling the affected lot due to "Failed Impurity (Deacetyl Diltiazem Hydrochloride) specification during stability testing and failed dissolution testing at FDA laboratory."

The Mumbai-based drug major had produced the lot at its Halol-based manufacturing facility in Gujarat. The affected lot was later distributed in the market by its US-based unit.

The company initiated the Class II nationwide recall (US) on January 13 this year.

As per USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

First Published: Sat, February 11 2023. 14:55 IST


RECENT NEWS

Coutts Sets Scope On New Continent

Coutts steps into private marketsCoutts, the private bank best known for serving Britain’s wealthiest families and the... Read more

From Cypherpunk To Citadel

How Crypto Moved from the Wild West to the Mainstream Financial SystemA long-form analysis of Bitcoin's journey from fri... Read more

ACB Securities: Building Scale, Trust & Innovation

ACB Securities: Building Scale, Trust and Innovation in Vietnam’s Capital MarketsACB Securities (ACBS) is emerging as ... Read more

War Risk Returns To Markets As VIX Surges

For most of the past year, global markets behaved as though geopolitical risk had largely disappeared. Inflation was eas... Read more

Stablecoin The Future Of Currency?

The payments system is undergoing a quiet but consequential shift. What was once the exclusive preserve of central banks... Read more

BoE Loosens Capital Rules

The Bank of England has taken a significant step towards easing post-crisis regulation by lowering its estimate of the c... Read more